Generic Product News: March PT Retail 2021
Generic product news from March 2021 PT Retail.
Manufactured by Glenmark Pharmaceuticals Limited
Compare to: Cialis
The FDA has approved Glenmark Pharmaceuticals’ Tadalafil Tablets USP 2.5, 5, 10, and 20 mg, indicated for erectile dysfunction and the treatment of benign prostatic hyperplasia (BPH). BPH is a common condition caused by an enlarged prostate gland, which can cause uncomfortable urinary symptoms and bladder, kidney, or urinary tract problems. The most common adverse reactions to Tadalafil Tablets include back pain, dyspepsia, flushing, headache, limb pain, myalgia, and nasal congestion. According to IQVIA sales data for the 12-month period ending November 2020, Cialis Tablets 2.5, 5, 10, and 20 mg had annual sales of approximately $125.5 million.
For More Information: glenmarkpharma.com
Venlafaxine hydrochloride ER
Manufactured by Camber Pharmaceuticals
Compare to: Effexor ER
Camber’s Venlafaxine Hydrocholoride ER tablets are indicated to treat major anxiety, depressive disorder, and panic disorder. By restoring the balance of norepinephrine and serotonin in the brain, the drug can improve energy levels and mood and may help restore individuals’ interest in daily living. The tablets are available in doses of 37.5, 75, 150, and 225 mg and in 30- and 90-count bottles. Adverse effects can include dizziness, drowsiness, fatigue, headache, nausea, stomach pain, and weakness.
For More Information: camberpharma.com
Manufactured by Dr Reddy’s Laboratories Ltd
Compare to: Uloric
Dr Reddy’s febuxostat tablets are indicated to lower uric acid levels in individuals with gout. Gout is a form of arthritis characterized by redness, severe and sudden pain attacks, swelling, and tenderness in joints, especially the joint at the base of the big toe. Nausea may occur when taking febuxostat, and serious liver disease or an increase in liver enzymes is a rare but serious adverse effect. The tablets are available in 40- and 80-mg strengths. The Uloric brand and generic had US sales of approximately $108 million for the 12 months ending October 2020, according to IQVIA data.
Abiraterone acetate tablets, 500 mg
Manufactured By Amneal Pharmaceuticals, Inc
Compare to: Zytiga
The FDA has approved an additional strength of 500 mg for Amneal’s Abiraterone Acetate Tablets USP 250 mg. The tablets are used in combination with prednisone for the treatment of metastatic prostate cancer, which affects approximately 50% of men diagnosed with local prostate cancer. Abiraterone acetate can have mild or serious adverse effects, including cough, diarrhea, edema, headache, fatigue, and joint pain. Amneal immediately initiated commercialization activities upon FDA approval.